Estabrook Capital Management’s Organogenesis Holdings ORGO Stock Holding History

Estabrook Capital Management’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$32K	–	340
2024 Q4	$32K	Hold	10,000	–	–	﹤0.01%	211
2024 Q3	$28.6K	Hold	10,000	–	–	﹤0.01%	226
2024 Q2	$28K	Hold	10,000	–	–	﹤0.01%	224
2024 Q1	$28.4K	Hold	10,000	–	–	﹤0.01%	234
2023 Q4	$40.9K	Hold	10,000	–	–	0.01%	216
2023 Q3	$31.8K	Hold	10,000	–	–	0.01%	228
2023 Q2	$33.2K	Hold	10,000	–	–	0.01%	234
2023 Q1	$21.3K	Hold	10,000	–	–	﹤0.01%	265
2022 Q4	$26.9K	Hold	10,000	–	–	﹤0.01%	251
2022 Q3	$32.4K	Hold	10,000	–	–	0.01%	231
2022 Q2	$48.8K	Hold	10,000	–	–	0.01%	215
2022 Q1	$76.2K	Hold	10,000	–	–	0.01%	194
2021 Q4	$92.4K	Buy	+10,000	New	+$106K	0.01%	188

Other funds holding ORGO

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Estabrook Capital Management's ORGO Position: Q1 2025 in Review

Estabrook Capital Management sold out of Organogenesis Holdings (ORGO) in Q1 2025, closing a stake of 10,000 shares — an estimated $32K sold.

Estabrook Capital Management first reported a position in ORGO in Q4 2021 and held it in 13 quarters. The position peaked at $92.4K in Q4 2021. 136 funds tracked by Wall St. Rank hold ORGO as of Q1 2025.

Estabrook Capital Management reported no remaining Organogenesis Holdings position as of Q1 2025 after selling out during the quarter.
Estabrook Capital Management sold 10,000 Organogenesis Holdings shares in Q1 2025, an estimated $32K.
Estabrook Capital Management first reported a position in Organogenesis Holdings in Q4 2021 and held it in 13 quarters.
Estabrook Capital Management's Organogenesis Holdings position peaked at $92.4K in Q4 2021.
136 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2025.

Based on Estabrook Capital Management's 13F filing for Q1 2025, filed 14 May 2025.